Axial Spondyloarthritis – Landscape & Forecast – Disease Landscape & Forecast
Copy/Paste the key inputs from the product brochure, per guidance from Marketing.
The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira, Janssen’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia); and IL-17 inhibitors (Novartis’s Cosentyx and Eli Lilly’s Taltz). The TNF-α inhibitors are the most widely prescribed biologics for AxSpA that is refractory to nonsteroidal anti-inflammatory drugs (NSAIDs). However, these agents face a competitive threat, both from the launch of cost-effective biosimilars and from the growing IL-17 class. In 2019, the FDA approved Cimzia for nonradiographic (nr)-AxSpA, marking the first FDA approval for this subpopulation, followed by both IL-17 inhibitors in June 2020. The recent approval of novel oral targeted therapies—JAK inhibitors (Pfizer’s Xeljanz and AbbVie’s Rinvoq)—for ankylosing spondylitis (AS) and the impending entry of an additional IL-17 inhibitor (UCB’s bimekizumab) will further shift market dynamics.
Questions answered:
- How large is the treatable AxSpA population, and how will diagnosis / drug-treatment rates change over time?
- What are interviewed experts’ insights on current treatment options for AS and nr-AxSpA? What clinical needs remain unfulfilled?
- What pipeline products are the most promising, and what key therapies are in early-phase development?
- What are interviewed experts’ opinions of the use of Xeljanz and Rinvoq for AS? What sales / uptake could JAK inhibitors secure in AxSpA?
- What are the drivers of and constraints in the AxSpA therapy market, and how will the market evolve over the forecast period?
Content highlights:
Geographies: United States, EU5, Japan
Primary research: Approximately 30 country-specific interviews with thought-leading rheumatologists; supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalent cases of AxSpA by country; AS and nr-AxSpA subpopulations.
Forecast: 10-year, annualized, drug-level sales and patient share of key AxSpA therapies through 2031, segmented by brands / generics and epidemiological subpopulations
Emerging therapies: Phase III: 1 drug; Phase II: 2 drugs
Product description:
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Axial Spondyloarthritis - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Key updates
- Q4 2022
- December 2022
- November 2022
- October 2022
- Q3 2022
- September 2022
- July 2022
- Q2 2022
- June 2022
- May 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Q4 2022
- Market outlook
- Key findings
- Market share of drug classes for axial spondyloarthritis: 2021
- Market share of drug classes for axial spondyloarthritis: 2031
- Axial spondyloarthritis SWOT analysis
- Market drivers and constraints
- What factors are driving the market for axial spondyloarthritis?
- What factors are constraining the market for axial spondyloarthritis?
- Drug-class-specific trends
- Major-market sales of NSAIDS for axial spondyloarthritis by drug class
- Major-market sales of TNF-alpha inhibitors for axial spondyloarthritis
- Major-market sales of branded vs. biosimilar TNF-alpha inhibitors
- Sales of TNF-alpha inhibitors for axial spondyloarthritis by market segment
- Major-market sales of IL-17 inhibitors for axial spondyloarthritis
- Sales of IL-17 inhibitors for axial spondyloarthritis by market segment
- Major-market sales of JAK inhibitors for axial spondyloarthritis
- Sales of JAK inhibitors for axial spondyloarthritis by market segment
- Key findings
- Forecast
- Market Forecast Assumptions - Axial Spondyloarthritis (2021-2031) - September 2022
- Market Forecast Dashboards - Axial Spondyloarthritis (2021-2031) - September 2022
- Etiology and pathophysiology
- Disease overview
- Classification criteria in axial spondyloarthritis
- Systems used to classify axial spondyloarthritis
- Presentation and disease progression
- Key pathways and drug targets
- Pathways involved in inflammation and bone damage in axial spondyloarthritis
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition
- Methods
- Sources used for total prevalent cases of axial spondyloarthritis
- Total prevalent cases of axial spondyloarthritis: 2021-2031 (thousands)
- Disease definition
- Methods
- Sources used for total prevalence of ankylosing spondylitis
- Total prevalent cases of ankylosing spondylitis: 2021-2031 (thousands)
- Disease definition
- Methods
- Sources used for total prevalent cases of nonradiographic axial spondyloarthritis
- Total prevalent cases of nonradiographic axial spondyloarthritis: 2021-2031 (thousands)
- Disease definition
- Methods
- Sources used for total prevalent cases of axial spondyloarthritis by HLA-B27 status
- HLA-B27-positive cases: 2021-2031 (thousands)
- Diagnosed prevalent cases of axial spondyloarthritis: 2021-2031 (thousands)
- Drug-treated prevalent cases of axial spondyloarthritis: 2021-2031 (thousands)
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for axial spondyloarthritis
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for axial spondyloarthritis
- Current treatments used for axial spondyloarthritis
- Market events impacting the use of key current therapies for axial spondyloarthritis
- Advantages and disadvantages of NSAIDs
- Expert insight: NSAIDs
- Advantages and disadvantages of conventional DMARDs
- Expert insight: conventional DMARDs
- Advantages and disadvantages of adalimumab
- Expert insight: adalimumab
- Advantages and disadvantages of etanercept
- Expert insight: etanercept
- Advantages and disadvantages of infliximab
- Expert insight: infliximab
- Advantages and disadvantages of Simponi
- Expert insight: Simponi
- Advantages and disadvantages of Cimzia
- Expert insight: Cimzia
- Advantages and disadvantages of Cosentyx
- Ongoing clinical development of Cosentyx
- Key ongoing clinical trials of Cosentyx in the treatment of axial spondyloarthritis
- Expert insight: Cosentyx
- Taltz
- Advantages and disadvantages of Taltz
- Ongoing clinical development of Taltz
- Key ongoing clinical trials of Taltz in the treatment of axial spondyloarthritis
- Expert insight: Taltz
- Advantages and disadvantages of Lumicef
- Expert insight: Lumicef
- Rinvoq
- Advantages and disadvantages of Rinvoq
- Ongoing clinical development of Rinvoq
- Key ongoing clinical trials of Rinvoq in the treatment of AxSpA
- Expert insight: Rinvoq
- Advantages and disadvantages of Xeljanz
- Expert insight: Xeljanz
- Medical practice
- Overview
- Factors influencing drug selection in axial spondyloarthritis
- Treatment decision tree for axial spondyloarthritis: United States
- Treatment decision tree for axial spondyloarthritis: Europe
- Treatment decision tree for axial spondyloarthritis: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in axial spondyloarthritis
- Top unmet needs in axial spondyloarthritis: current and future attainment
- Expert insight: unmet need in axial spondyloarthritis
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for axial spondyloarthritis
- Estimated launch dates of key emerging therapies for the treatment of axial spondyloarthritis
- Bimekizumab profile
- Key ongoing clinical trials of bimekizumab in the treatment of axial spondyloarthritis
- Analysis of the clinical development program for bimekizumab
- Expert insight: bimekizumab
- Expectations for launch and sales opportunity of bimekizumab in axial spondyloarthritis
- Early-phase pipeline analysis
- Select compounds in Phase II development for axial spondyloarthritis
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in axial spondyloarthritis: United States
- General reimbursement environment: United States
- Key market access considerations in axial spondyloarthritis: EU5
- General reimbursement environment: EU5
- Key market access considerations in axial spondyloarthritis: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Axial spondyloarthritis bibliography
- Key findings
Swati Kinger, M.B.A., Healthcare Research & Data Analyst, Immune and Inflammation. Ms. Kinger’s focus is the axial spondyloarthritis market. Previously, she was an associate consultant for a life sciences firm, where she worked on syndicated offerings and ad-hoc requests involving patient journeys, market assessment, and competitive intelligence. She holds a bachelor’s degree in pharmacy from Delhi University and an M.B.A. in pharmacy from the National Institute of Pharmaceutical Education and Research in India.
Latashree Goswami, M.P.H., is an associate epidemiologist at Clarivate. Her areas of interest include oncology and autoimmune disorders. She holds an M.P.H. from the Indian Institute of Public Health, where she specialized in health economics, financing, and policy, and a B.D.S. from India’s ITS Dental College.